Skip to content
Prescribed CJC-1295

CJC-1295 background to bring to a doctor. Nothing is prescribed here.

Menu

CJC-1295 access and prescriptions

A prescription, an approved medicine and an ingredient permitted for compounding are different things. Each needs its own answer when CJC-1295 is being discussed.

An adult writing in an unmarked notebook at a home desk, viewed from behind.
Home / CJC-1295 access and prescriptions

A prescription begins with an assessment

A prescribing decision depends on a person's medical history, current medicines, the reason for considering treatment and the available evidence. A licensed provider may decide that a treatment is inappropriate. A request or an online selection does not itself establish that a prescription will be issued.

Telehealth can be a way to hold a clinical assessment, subject to the rules that apply where a person is located. It does not change a compound's approval status or the ingredient rules for compounding. This site provides no consultations, treatment or prescriptions. It cannot decide whether any preparation is appropriate for a particular person, and the explanations here are not medical or legal advice.

What FDA approval would mean

CJC-1295 is not an FDA-approved drug. There is no approved label defining an indication, a dose or an FDA-reviewed set of warnings for its use. The FDA's 2024 evaluation describes limited human evidence and concerns about the different related forms. Early hormone findings are not a substitute for the evidence needed to establish a treatment's benefits and risks.

Compounded medicines are not FDA-approved either. As the FDA explains about compounding, the agency does not review each preparation for safety, effectiveness and quality before it reaches patients. A prescription and the involvement of a licensed professional do not turn a compounded preparation into an approved drug. The two routes also differ in the standards and oversight that apply.

What the withdrawn nomination means

On its page current as of April 22, 2026, the FDA lists CJC-1295 among bulk drug substances nominated but withdrawn. It is no longer in that page's Category 2 table. The safety concerns remain published beside its entry. The agency does not provide a substance-specific date for the move between those tables.

Withdrawal is not a favorable safety decision, clearance for compounding or a Category 1 placement. The Section 503A framework has separate requirements for the raw ingredients used in patient-specific compounding. The FDA's review found no applicable official quality standard for CJC-1295 and no approved drug containing it. A committee discussion, a nomination or a description on a website cannot stand in for meeting those legal requirements.

When a blend is being discussed

A prescription route may refer to a blend containing CJC-1295 and ipamorelin rather than CJC-1295 alone. That distinction matters. The exact ingredients, the presence or absence of DAC and the preparation all need to be identified. Evidence for one compound does not establish the benefits or safety of their combination.

A named route also does not settle the FDA or compounding questions described above. Those questions remain relevant alongside an individual clinical decision. Availability and regulatory permission cannot be treated as equivalent. The following example concerns a blend only, rather than a standalone CJC-1295 preparation.

Questions that keep the distinctions visible

Useful questions include which active ingredients are proposed, which form of CJC-1295 is involved, what evidence supports the intended use and what lawful basis applies to the preparation. It is also reasonable to ask how personal risks, alternatives and possible adverse effects would be discussed. None of these questions can be answered by a product name alone.

A prescriber decides whether treatment is appropriate, while compounding rules remain a separate constraint. This page cannot guarantee access, eligibility or an outcome. For the biological evidence behind the discussion, visit research. For the meaning of the linker and the difference between forms, visit the FAQ. The references link the official documents so their scope and wording can be examined directly.

Follow the findings to their sources.

View the references